[1] [1] MISHRA S K, GAO Y G, ZOU X, et al. Emerging roles for human glycolipid transfer protein superfamily members in the regulation of autophagy, inflammation, and cell death ［J］. Progress in Lipid Research, 2020, 78: 101031.

[2] [2] KJELLBERG M A, MATTJUS P. Glycolipid transfer protein expression is affected by glycosphingolipid synthesis ［J］. PLoS One, 2013, 8(7): e70283.

[3] [3] MALININA L, PATEL D J, BROWN R E. How alpha-helical motifs form functionally diverse lipid-binding compartments ［J］. Annual Review of Biochemistry, 2017, 86: 609-636.

[5] [5] GOMEZ-LARRAURI A, PRESA N, DOMINGUEZ-HERRERA A, et al. Role of bioactive sphingolipids in physiology and pathology ［J］. Essays in Biochemistry, 2020, 64(3): 579-589.

[6] [6] OGRETMEN B. Sphingolipid metabolism in cancer signalling and therapy ［J］. Nature Reviews Cancer, 2018, 18(1): 33-50.

[7] [7] SIMANSHU D K, ZHAI X, MUNCH D, et al. Arabidopsis accelerated cell death 11, ACD11, is a ceramide-1-phosphate transfer protein and intermediary regulator of phytoceramide levels ［J］. Cell Reports, 2014, 6(2): 388-399.

[9] [9] MISHRA S K, GAO Y G, DENG Y, et al. CPTP: a sphingolipid transfer protein that regulates autophagy and inflammasome activation ［J］. Autophagy, 2018, 14(5): 862-879.

[10] [10] CRAIG A J, VON FELDEN J, GARCIA-LEZANA T, et al. Tumour evolution in hepatocellular carcinoma ［J］. Nature Review Gastroenterology Hepatology, 2020, 17(3): 139-152.

[11] [11] VILLANUEVA A. Hepatocellular carcinoma ［J］. The New England Journal of Medicine, 2019, 380(15): 1450-1462.

[12] [12] HARTKE J, JOHNSON M, GHABRIL M. The diagnosis and treatment of hepatocellular carcinoma ［J］. Seminars in Diagnostic Pathology, 2017, 34(2): 153-159.

[13] [13] BAI K H, HE S Y, SHU L L, et al. Identification of cancer stem cell characteristics in liver hepatocellular carcinoma by WGCNA analysis of transcriptome stemness index ［J］. Cancer Medicine, 2020, 9(12): 4290-4298.

[14] [14] VASAIKAR S V, STRAUB P, WANG J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types ［J］. Nucleic Acids Research, 2017, 46(D1): D956-D963.

[15] [15] CHANDRASHEKAR D, BASHEL B, BALASUBRAMANYA S, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses ［J］. Neoplasia (New York, NY), 2017, 19(8): 649-658.

[16] [16] SZáSZ A M, LáNCZKY A, áDáM N, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1 065 patients ［J］. Oncotarget, 2016, 7(31): 49322-49333.

[17] [17] NAGY A, LANCZKY A, MENYHART O, et al. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets ［J］. Surface Science Reports, 2018, 8(1): 9227.

[18] [18] TANG Z, LI C, KANG B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses ［J］. Nucleic Acids Research, 2017, 45(W1): W98-W102.

[19] [19] LI T, FU J, ZENG Z, et al. TIMER 2.0 for analysis of tumor-infiltrating immune cells ［J］. Nucleic Acids Research, 2020, 48(W1): W509-W514.

[20] [20] LI T, FAN J, WANG B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells ［J］. Cancer Research, 2017, 77(21): e108-e110.

[21] [21] LI B, SEVERSON E, PIGNON J C, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy ［J］. Genome Biology, 2016, 17(1): 174.

[22] [22] WEI R, QIU H, XU J, et al. Expression and prognostic potential of GPX1 in human cancers based on data mining ［J］. Annals of Translational Medicine, 2020, 8(4): 124.

[23] [23] WU B, TANG X, KE H, et al. Gene regulation network of prognostic biomarker YAP1 in human cancers: an integrated bioinformatics study ［J］. Pathology Oncology Research, 2021, 27: 1609768.

[24] [24] ZHOU Y, ZHOU B, PACHE L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets ［J］. Nature Communications, 2019, 10(1): 1523.

[25] [25] LONG J, ZHANG L, WAN X, et al. A four-gene-based prognostic model predicts overall survival in patients with hepatocellular carcinoma ［J］. Journal of Cellular and Molecular Medicine, 2018, 22(12): 5928-5938.

[26] [26] IASONOS A, SCHRAG D, RAJ G V, et al. How to build and interpret a nomogram for cancer prognosis ［J］. Journal of Clinical Oncology, 2008, 26(8): 1364-1370.

[27] [27] LIU J, LICHTENBERG T, HOADLEY K A, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics ［J］. Cell, 2018, 173(2): 400-416. e11.

[28] [28] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］. A Cancer Journal for Clinicians, 2021, 71(3): 209-249.

[29] [29] ZHENG R, QU C, ZHANG S, et al. Liver cancer incidence and mortality in china: temporal trends and projections to 2030 ［J］. Chinese Journal of Cancer Research, 2018, 30(6): 571-579.

[30] [30] LI S, YANG F, REN X. Immunotherapy for hepatocellular carcinoma ［J］. Drug Discoveries Therapeutics, 2015, 9(5): 363-371.

[31] [31] TABASSUM R, RAMO J T, RIPATTI P, et al. Genetic architecture of human plasma lipidome and its link to cardiovascular disease ［J］. Nature Communications, 2019, 10(1): 4329.

[32] [32] JUNG K, KIM J H, CHEONG H S, et al. Gene expression profile of necrotizing enterocolitis model in neonatal mice ［J］. International Journal of Surgery, 2015, 23(part A): 28-34.